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Available online 6 May 2017Elderly with late-onset recurrent respiratory tract infections (RRTI) often have specific anti-polysaccharide anti-
body deficiency (SPAD). We hypothesized that late-onset RRTI is caused by mild immunodeficiencies, such as
SPAD, that remain hidden through adult life. We analyzed seventeen elderly RRTI patients andmatched controls.
We determined lymphocyte subsets, expression of BAFF receptors, serum immunoglobulins, complement path-
ways, Pneumovax-23 vaccination response and genetic variations in BAFFR andMBL2. Twelve patients (71%) and
ten controls (59%) had SPAD. IgAwas lower in patients than in controls, but other parameters did not differ. How-
ever, a high percentage of both patients (53%) and controls (65%) were MBL deficient, much more than in the
general population. Often, MBL2 secretor genotypes did not match functional deficiency, suggesting that func-
tional MBL deficiency can be an acquired condition. In conclusion, we found SPAD and MBL deficiency in many
elderly, and conjecture that at least the latter arises with age.









Primary immunodeficiencies (PIDs) such as severe combined immu-
nodeficiency (SCID) or chronic granulomatous disease (CGD) are gener-
ally associated with clinical manifest infections in the first stages of life
and diagnosed by pediatric specialists. Infants and children with failure
to thrive, a positive family history or an early need for intravenous anti-
biotics should be screened for PID [1].
In the elderly, ‘wear and tear’ of the human body results in reduced
organ function, overstretches the system [2], and places greater demand
on normally redundant elements of host defense to infection. This may-cell maturation antigen; CGD,
immunodeficiency; MBL, man-
s, pneumococcal polysaccharide
ory tract infections; SCID, severe
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s Diseases, Leiden University
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osse).
. This is an open access article underrevealmild defects in the immune system such as skewed lyonization in
female carriers of X-linked CGD [3]. We hypothesized that some mild
PIDs, for example defective antibody production in response to pneu-
mococcal polysaccharide antigens (PnPs) – also referred to as specific
anti-polysaccharide antibody deficiency (SPAD) [4]—, may not emerge
until older age with recurrent respiratory tract infections (RRTI). In our
hypothesis, SPAD may be caused by a late onset diminished expression
on B cells of B-cell activating factor (BAFF) receptors, namely the BAFF
receptor (BAFF-R), the transmembrane activator and cyclophilin ligand
interactor (TACI) and the B-cell maturation antigen (BCMA) (reviewed
in [5]), and thus lead to RRTI in these elderly persons. One of the two li-
gands binding to these three receptors is BAFF, a cytokine that is in-
duced by T-cell independent antigens such as PnPs [6]. The interaction
of BAFF with its receptors, is essential for B cell maturation and subse-
quent antibody production. Therefore, it is possible that BAFF-R defi-
ciency causes defective antibody production in SPAD. Indeed, children
below the age of two are constitutively deficient in their responses to
PnPs [7], which is likely due to low expression of these BAFF receptors
[8].
Defects in BAFF-R play a role in known, serious antibody deficiencies
with low levels of IgG, notably in common variable immunodeficiencythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the respiratory tract, low IgG (b5 g/L) and low IgA and/or IgM, and is
generally diagnosed before the age of fifty [9]. First, some patients
with CVID have reduced BAFF-R and increased TACI expression in asso-
ciation with high BAFF serum levels [10]. Second, a single nucleotide
polymorphism in the BAFF-R contributes to CVID [11]. Third, BAFF-R de-
ficiency led to adult-onset antibody deficiency with very low IgG in two
siblings from a consanguineous marriage [12].
For our observational study we selected older adult RRTI patients
who did not fulfill CVID criteria and either did not have RRTI earlier in
life or experienced respiratory infections that were previously not
viewed as important enough for analysis. We compared both their in-
nate and adaptive immunity to age- and gender-matched controlswith-
out RRTI.
2. Materials and methods
2.1. Inclusion of patients and controls
Elderly patients (age N 45 years) with late-onset RRTI were selected
from the LUMC outpatient clinic for infectious diseases from January
2010 to January 2014. The criteria for inclusion were: two or more bac-
terial or viral sino- and/or pulmonary infections in the previous year,
and no RRTI diagnosed in early adulthood, adolescence or childhood.
Exclusion criteria were a known primary immunodeficiency, including
CVID (defined by a.o. IgG b5 g/L [9]), or secondary immunodeficiency
such as malignancy or treatment with immunosuppressive agents.
Three of the patients had cancer 14–20 years before the onset of RRTI,
current comorbidities (such as hypertension and mild asthma in a few
patients) were deemed not to affect the immune system. The patients
did not have allergic diseases, and were all but two non-smokers (of
three the smoker status was unknown). As part of the diagnostic
work-up, patients were vaccinated with the 23-valent polysaccharide
vaccine Pneumovax-23 (PPV-23) against Streptococcus pneumoniae
and followed-up for the humoral response to PnPs vaccine components
one month later.
We recruited age- and gender-matched controls without RRTI from
visitors of the LUMC travel clinic and hospital staff. Exclusion criteria
were a history of RRTI, previous vaccination with PPV-23 or conjugated
Prevenar and/or a known primary or secondary immunodeficiency.
Controls completed a questionnaire, were immunized with PPV-23
and blood was sampled before, and one month after vaccination. The
controls did not have allergic diseases, they were not asked whether
they were smokers or not. All participants provided informed consent
and the study was approved by the Medical Ethical Committee of the
Leiden University Medical Center (protocol P15-058).
2.2. DNA isolation and genotyping
DNAwas isolated from blood using standard methods [13]. The sin-
gle nucleotide polymorphism (SNP) rs77874543 in TNFRSF13C
(encoding BAFF-R) was genotyped as described by Pieper et al. [11].
MBL2 secretor genotypes were determined by PCR (primers and condi-
tions available on request) and sequencing.
2.3. Phenotyping of lymphocytes
Wedetermined B cells, NK cells and CD4+andCD8+T-cell subsets,
differentiation stages within the B-cell population and the T-cell sub-
sets, and receptor expression of the BAFF receptors BAFF-R, BCMA and
TACI on B-cell differentiation stages by flow cytometry. Peripheral
blood mononuclear cells (PBMC) were obtained from patients and
healthy donors by Ficoll density gradient separation and stored in liquid
nitrogen until analysis. Thawed PBMCwere stainedwith fluorochrome-
labeled antibodies against the indicated cell surface antigen (see supple-
mental Table 1). To facilitate lymphocyte gating PBMC samples werestained for CD45, CD14, CD33, CD235a (glycophorin A). Fc-receptor
blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) was
used according tomanufacturer's instructions to prevent aspecific bind-
ing of antibodies. We added DAPI (4′,6-diamidino-2-phenylindole) to
discriminate between live and dead cells. Samples were measured on
a BD Biosciences LSR II flow cytometer (San Jose, CA) with DIVA soft-
ware, and data analyzed by Kaluza software (Beckman-Coulter, Brea,
CA).
Phenotypical definitions of T-cell differentiation stages were: naïve
T-cells: CD45RA+CCR7+; central memory T-cells: CD45RA−CCR7+;
antigen experienced CD4+ T-cells CD45RA+/−CCR7−: early
CD28+CD27+; intermediate CD28+CD27−; late CD28−CD27−;
antigen experienced CD8+ T-cells CD45RA+/−CCR7−: early
CD28+CD27+; intermediate CD28−CD27+; late CD28−CD27−.
Phenotypical definitions of B-cell differentiation stages were:
immature B-cells: CD24++CD38++IgM+IgD−; transitional B-cells:
CD24++CD38++IgM+IgD+; naïve B-cells: IgMdullIgD++CD27−;
natural effector B-cells: IgM++IgDdullCD27+; double negative memory
B-cells: IgM+/− IgD−CD27− andwithin this subset IgA+ and IgG+ cells;
IgM committed memory B cells: IgM+IgD−CD27+; switched memory
B-cells: IgM− IgD−CD27+ and within this subset IgA switched (IgA+)
and IgG switched (IgG+) cells. Within B-cell differentiation stages
expression of three BAFF receptors was measured: BAFF-R (CD268),
TACI (CD267) and BCMA (CD269).
2.4. Laboratory parameters
Levels of serum immunoglobulins (IgG, IgG subclasses, IgA and
IgM); activity of the classical pathway (CP), of the alternative pathway
(AP) and of Mannose binding lectin (MBL); concentrations of comple-
ment components (C1q, C4 and C3); IgG antibody titers to PnPs (11 an-
tigensmeasured before 2014: type 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and
23; 9 antigens measured from 2014 onwards: type 6B, 8, 9V, 14, 15B,
19F, 20, 23, 33F) were measured by standard assays [14–16].
A normal response to PPV-23 is defined as responses to N70% (e.g. 9
out of 11) of the vaccine components with an antibody titer ≥1 μg/mL
after vaccination. Presence of antibodies against VZV, EBV, Rubella,
and CMV were determined in various blood samples according to stan-
dard diagnostic procedures. MBL protein was measured in serum sam-
ples with the MBL DuoSet ELISA (DY2307, R&D Systems, Minneapolis,
MN).
2.5. Statistical analyses
Data were analyzed by SPSS version 20 (IBM SPSS Inc., Chicago, IL).
The non-parametric Mann-Whitney U test was used for comparison of
continuous data. For categorical data, the Pearson χ2 test was used ex-
cept where indicated otherwise. Differences with a p-value b 0.05
were considered statistically significant.
3. Results
3.1. Response to polysaccharide antigens is deficient in many elderly
individuals
Before vaccination 14 out of 15 patients (2 not determined) and all
17 controls lacked adequate responses to PnPs. Twelve out of 17 elderly
patients with late-onset RRTI and 10 out of 17 healthy age- and gender-
matched controls had inadequate IgG antibody production to PnPs after
vaccinationwith PPV-23 (Table 1). Every individualwas seropositive for
some of the antigens, the responses are on a continuum rather than an
‘all or nothing’ effect and were not correlated with age or presentation
(only upper, only lower, or combined upper and lower RRTI). To evalu-
ate whether the individuals with an inadequate response to PnPs were
overall deficient in antibody productionwemeasured the production of
antibodies against protein antigens from common viruses (VZV, EBV,
Table 1






Gender, male (%) 6 (35%) 6 (35%)
Age, mean (median; range) 63.0 (61; 46–90) 62.6 (61; 48–78)




Chronic otitis media with effusion 4
Response to pneumococcal antigens
Normalb 5 7
Low or absent 12 10
Positive responses, mean % ± sem 55 ± 6% 72 ± 4% 0.034
Response to protein antigensc
Positived 17 out of 17 16 out of 16e
a Late onset recurrent respiratory tract infections, some patients have more than one problem.
b Positive responses (IgG antibody titer ≥1 μg/mL) to N70% of the vaccine antigens after Pneumovax-23 vaccination.
c Antibodies analyzed against: VZV, EBV, Rubella, CMV.
d One or more positive responses.
e Not determined in one control.
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one or more protein antigens (Table 1).
3.2. IgG and IgM are comparable in patients and controls, IgA is lower in
patients
Inability to produce certain immunoglobulin isotypes can result in
an increased susceptibility to infections. Levels of serum IgG, IgM and
IgG subclasses did not differ between patients and controls (Fig. 1A,
C–G), while IgA was significantly lower (p = 0.008) in RRTI patients
than in controls (Fig. 1B and Table 2). IgA was undetectable in two pa-
tients and above the normal range (0.7–4.0 g/L) in only one patient.
All controls had IgA levels within the normal range or above (the latter
in two individuals) (Fig. 1B). There was no correlation between age and
IgA concentration.
3.3. Haematological data are comparable between patients and controls
Cell numbers in blood from RRTI patients and controls were overall
comparable, except for thrombocytes that were marginally higher in
RRTI patients (Table 2). Counts of lymphocyte populations, i.e., T cells
(CD3+), NK cells (CD3−, CD7+, CD16+/−, CD56+) and B cells
(CD19+CD20+), were comparable between patients and controls
(Table 2).
3.4. B cells, T cell subsets and differentiation stages are comparable between
patients and controls
B cells, T-cell subsets and B- and T-cell differentiation stages were
analyzed by flow cytometry. Cell numbers at differentiation stages
within the CD4+ andCD8+ T-cell subsets, i.e., naïve, centralmemory, ef-
fector memory and end-stage effector cells were similar in patients and
controls (data not shown). Likewise, numbers of all B-cell differentia-
tion stages, i.e., transitional, naïve, natural effector, IgM committed
memory; switched memory (SMB) IgA+, switched memory (SMB)
IgG+, double-negative (DN) IgA+ memory, double-negative (DN)
IgG+ memory (Fig. 2A–H), immature and switched memory (data not
shown) were similar in both groups. The two lowest measurements in
the switched memory IgA+ B cells in Fig. 2E and G correspond, as is to
be expected, with the two patients with undetectable IgA in their
serum.3.5. Expression intensity of BAFF binding receptors is similar between pa-
tients and controls
The BAFF receptors TACI, BCMA and BAFF-R are known to play an
important role in B-cell differentiation. To determine whether altered
expression may account for RRTI, or at least for the reduced response
to PnPs in many of our RRTI patients, we measured expression of
these receptors on various B-cell differentiation stages by flow cytome-
try. BCMAwas not at all detectable on any B cell from the transitional to
the switched memory stage (data not shown). While TACI expression
was low but detectable on all B cell differentiation stages analyzed, i.e.,
transitional, naïve, natural effector, double-negative, IgM committed
and switched B cells – as exemplified for naive B cells and switched
memory B cells (Fig. 3A–B)— expression was not different between pa-
tients and controls. BAFF-R was also expressed on all B-cell differentia-
tion stageswith nodifferences betweenpatients and controls (Fig. 3C–D
and data not shown). While TACI expression was highest on switched
memory B cells and lowest on naïve B cells, this was the other way
around for BAFF-R expression (Fig. 3A-D).
A variant in TNFRSF13C, rs77874543, that results in an amino acid
change (P21R) in BAFF-R, is known to affect BAFF binding and, thereby,
BAFF-induced NF-κB activation that is needed for B-cell activation [11].
We genotyped this variation to determine whether it is more prevalent
in RRTI patients than in controls. Two individuals in each group were
heterozygous for this variation (Table 3). BAFF-R expression for these
individuals was always below themedian in the various B-cell differen-
tiation stages (Fig. 3C-D and data not shown).3.6. MBL deficiency in many elderly controls
Various components of the complement pathways were analyzed
to determine whether a deficiency in any of these could contribute to
RRTI observed in the patients. Concentrations of C1q, C4 and C3 were
not significantly different between the two groups (Table 2).
Percentages of complement activation through the classical and
alternative pathways were also similar between the groups, with
only one patient having alternative pathway activation below the
normal range (Table 2).
Based on the functional activity of MBL, two patients were partial
and seven were completely MBL deficient (9/17 patients were
Fig. 1. Immunoglobulins are overall low in the elderly, IgA is lower in patients. Immunoglobulins (in g/L)were determined in serum from17RRTI patients and 17 controls (C–G) except for
IgM and IgA (A–B) where only data for 16 patients are available. The black horizontal line indicates the median, grey areas indicate the reference values for adults.
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completely MBL deficient (11/17 controls were deficient). These low
MBL activation percentages were not significantly different between
the two groups (Table 2). Since such a striking number of individuals
in both groups had no MBL activity, we repeated MBL measurements
in most samples, but this did not alter the outcomes. Subsequently,
we determined MBL2 secretor genotypes by sequencing the promoter
region and exon 1 of the MBL2 gene. These two parts of MBL2 contain
the polymorphisms and mutations that determine the MBL2 secretor
genotype. Interestingly, we found a significant difference in distribution
ofMBL2 genotypes (p=0.003). Low or deficient genotypes were more
frequent in controls (n = 10) than in patients (n = 2) (Table 3). Even
more surprising, in many of the individuals, i.e., 9 RRTI patients and 6controls, the secretor genotype (high, intermediate or low) did not
match the observed partial or complete functional deficiency (Fig. 4,
supplemental Table 2). Of note, MBL2 secretor genotype was nonethe-
less associated with MBL activity (p = 0.012).
To rule out an acquired inhibiting factor in the serum that could
cause the discrepancy betweenMBL2 secretor genotypes andMBL activ-
ity, wemeasuredMBL activity of a pool of individuals with highMBL ac-
tivity combined with various dilutions of sera from four elderly
individuals with high secretor genotype and low or absentMBL activity.
Inhibition of MBL activity by any of the sera was not detected (data not
shown). TodeterminewhetherMBLprotein production is reduced in el-
derly individuals at advanced age, we measured the MBL protein in the
sera of 22 of the individuals. Indeed, we found that MBL protein in the
Table 2







Leukocytes, in 109/L 6.3 ± 0.6 5.7 ± 0.5 n.s.
Eosinophils, in 109/L 0.17 ± 0.02 0.19 ± 0.04 n.s.
Basophils, in 1012/L 31 ± 5 32 ± 5 n.s.
Neutrophils, in 109/L 3.88 ± 0.46 3.37 ± 0.38 n.s.
Lymphocytes, in 109/L 1.75 ± 0.20 1.66 ± 0.15 n.s.
Monocytes, in 109/L 0.48 ± 0.05 0.46 ± 0.05 n.s.
Erythrocytes, in 1012/L 4.5 ± 0.1 4.6 ± 0.1 n.s.
Thrombocytes, in 109/L 260 ± 12 232 ± 11 0.049
Haemoglobin, in mmol/L 8.3 ± 0.2 9.0 ± 0.2 n.s.
Cell subsets, mean per μL
Lymphocytes 1753 ± 201 1661 ± 154 n.s.
T cells 1298 ± 168 1114 ± 108 n.s.
NK cells 213 ± 25 294 ± 37 n.s.
B cells 208 ± 55 223 ± 43 n.s.
Immunoglobulins, mean in g/L
IgAa 1.5 ± 0.3 2.2 ± 0.2 0.008
IgG 9.8 ± 0.9 9.6 ± 0.5 n.s.
IgG1 6.4 ± 0.7 6.2 ± 0.3 n.s.
IgG2 2.8 ± 0.3 2.9 ± 0.2 n.s.
IgG3 0.4 ± 0.05 0.3 ± 0.04 n.s.
IgG4 0.3 ± 0.1 0.5 ± 0.1 n.s.
IgMa 0.9 ± 0.1 0.9 ± 0.1 n.s.
Complement, mean
C3, in g/La 1.1 ± 0.05 1.0 ± 0.04 n.s.
C4, in mg/La 229 ± 14.3 217 ± 13 n.s.
C1q, in mg/La 136 ± 10.5 147 ± 5 n.s.
CP activation, in % 97 ± 2.6 92 ± 2.4 n.s.
AP activation, in % 73 ± 5.1b 67 ± 3.5 n.s.
MBL activation, in % 30 ± 9.1 20 ± 8.7 n.s.
MBL low or absentc 9 out of 17 11 out of 17 n.s.
All means are indicated as mean ± the standard error of the mean. MBL = mannose binding lectin; CP = classical pathway; AP = alternative pathway; n.s. = not significant.
a Data from 1 patient are lacking.
b Only one patient was deficient.
c Normal is defined as N10% activation, low as 1–10% activation, absent as 0% activation.
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spite their high or intermediateMBL2 secretor genotype (Supplemental
Fig. 1). Therewas no correlation between age andMBL concentration or
MBL activity in these elderly individuals.
4. Discussion
In this observational study we analyzed 17 elderly patients with late
onset RRTI and 17 age- and gender-matched controls to identify a subtle
immunodeficiency in the RRTI patients. Although the number of posi-
tive responses one month after PPV-23 vaccination was significantly
lower in patients than in controls, we foundmany elderly with deficient
responses in both groups. The presence of SPAD in such a high number
of patients and controls (71% and 59% respectively) suggests that this
deficiency does not offer an explanation for late onset RRTI in our pa-
tients. In search for further clarification, we assessed for, but did not
find, differences between patients and controls, neither in various
blood cells and lymphocyte subsets, nor in B- and T-cell differentiation
stages and BAFF receptor expression. Surprisingly, we did find a higher
frequency of deficient/low MBL2 secretor genotypes in controls than in
patients, suggesting a protective effect of lowMBL activity against RRTI.
Furthermore, functional MBL activity was much lower than we expect-
ed in our elderly population at large, in patients and controls, often
paralleling low MBL protein serum concentrations but notMBL2 secre-
tor genotypes.
In some countries, but not in The Netherlands, it is common practice
to immunize elderly (≥65 years old) with PPV-23 to protect them from
infection with S. pneumoniae, a frequently found airway pathogen.
Dutch immunologists and infectious disease specialists use PPV-23 to
diagnose potential antibody deficiency syndromes in RRTI patients.
We found that the response to the pneumococcal polysaccharideantigens in PPV-23 was deficient not only in patients but also in many
controls. To determinewhether these elderly people, similar to CVID pa-
tients, have a general inability to produce antibodies, we analyzed over-
all immunoglobulin production and antibody production in response to
protein antigens such as CMV and EBV. Production of immunoglobulin
(sub)classes was comparable between patients and controls except for
IgA which was significantly lower in the patients. None of the individ-
uals had CVID or a generalized hypogammaglobulinemia. In addition,
antibodies against protein antigens were present in all individuals. Ad-
mittedly, it would be interesting to assess the response to a neoantigen
(such as tick-borne encephalitis virus) as well, as the protein antibodies
we assessed may be secreted by long-lived plasma cells; this will be
subject of further study. In addition, it is interesting to determine
whether the positive responses to pneumococcal antigens that are pres-
ent 1 month after vaccination are still detectable at levels similar be-
tween the patients and controls 6 to 12 months after vaccination, as it
is conceivable that in the patients the response is more transient. Re-
gardless, our data indicate that the deficient antigen responses in the
twelve patients and ten controls are specific for pneumococcal antigens
(SPAD), and not representative of a general problem in antibody
production.
Our results show that in the elderly, a lowor absent response to PPV-
23 vaccination does not predispose to RRTI, and might be more justly
interpreted as a sign of an advanced age. This suggests either that lack-
ing responses to PPV-23 vaccination are not the cause of RRTI, or that
the current definition of an adequate response (N70% of the antigens in-
duced an antibody titer of ≥1 μg/mL) should be re-investigated in the el-
derly: since both the RRTI group and the healthy controls have very
similar low responses, these low responses may actually be adequate.
In addition, the IgG antibody titers routinely measured in response
to PPV-23 vaccination may not be the only relevant antibody titers. In
Fig. 2. B-cell differentiation stages are similar between patients and controls. B-cell differentiation stages in patients and controls (A–H). The two closed circles in E and G at the bottom of
the graph correspond to the two patients who do not produce detectable IgA. The black horizontal line indicates themedian. Lower detection level is 0.1 cells/μL for these graphs. SMB=
switched memory B cells. DN= double-negative (IgD−CD27−).
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cells, also known as “innate” IgM memory B cells, and consequently
lack of IgM antibodies, has been shown to be correlated with increased
susceptibility to pneumococcal infections and lack of response to poly-
saccharide vaccines [17,18], suggesting IgM antibodies may be essential
against pneumococcal infections. In our subjects, who are not asplenic
and do not have CVID,we did notmeasure IgM antibodies against pneu-
mococcal antigens. However, natural effector B cells (as well as germi-
nal center-dependent IgM+ committed memory B cells) are present
in normal amounts.
We did not find a difference between the controls and the RRTI
patients. However, the RRTI group included patients with upper re-
spiratory tract infections only (n = 5, recurrent otitis media and/orrhino sinusitis), patients with lower respiratory tract infections
only (n = 5, bronchitis and/or recurrent pneumonia), as well as pa-
tients with combined lower and upper respiratory tract infections
(n = 7). As the immune impairment in these RRTI subgroups may
be different, we have analyzed the various B- and T-cell subsets
and pneumovax responses in these subgroups. Pneumovax re-
sponses and T-cell subsets do not differ between the subgroups.
We do observe a small but significant difference between controls
and patients with combined upper and lower RRTI in total B cells
(p b 0.03), natural effector B cells (p b 0.03), switched B cells
(p b 0.006), SMB IgA B-cells (p b 0.002), and DN memory IgA B-
cells (p b 0.05) but not between the controls and either of the
lower or the upper RRTI subgroup (Supplemental Fig. 2).
Fig. 3. TACI and BAFF-R are expressed on naive and switchedmemory B cells. Mean florescence intensity of naive B cells (A, C) and switchedmemory B cells (B, D) labeledwith anti-CD267
(TACI) antibody (A, B) or anti-CD268 (BAFF-R) antibody (C, D). The black horizontal line indicates themedian.MFI=mean fluorescence intensity. Thefilled grey circles depict individuals
heterozygous for the SNP rs77874543 in TNFRSF13C (encoding BAFF-R).
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sions of BAFF receptors, in particular BAFF-R and TACI, than controls
[10,11]. Hence, we supposed that RRTI in our patients could be caused
by lower expression of one of the BAFF receptors on their B cells. We
were also interested in the cell types that express TACI and BCMA be-
cause, while BAFF receptors have different expression levels depending
on the stage of B-cell differentiation and activation [19], it is controver-
sial on exactly which cells TACI and BCMA are expressed (discussed in
[19]). We were able to detect BAFF-R on various B-cell differentiation
stages, with highest expression on naive B cells and lowest expression
on memory B cells. Indeed, in normal ageing, memory B cells replace
naive B cells within the B cell repertoire. However, we did not detect a
difference in expression of BAFF-R between RRTI patients and controls.
BCMA is reported to be expressed on CD138+B cells isolated from ton-
sils and bone marrow [19], cells not analyzed in this study. Indeed,
BCMA was not detectable on the various peripheral blood B-cell differ-
entiation stages we analyzed. TACI is expressed predominantly by
memory B cells [19], only on tonsillar B cells [20,21], or on mature
naive and memory B cells [22]. In accordance, we detected a low
amount of TACI expression on switched and natural effector B cells
and expression at very low intensity on naive B cells from blood.
Again, we did not detect a difference in TACI expression between RRTI
patients and controls.Table 3









Low XA/XA or YA/O 2
Deficient XA/O or O/O 0
a MBL2 secretor genotypes according to Bernig et al. [32].
b Fisher's exact test.The BAFF receptor BAFF-R is essential for B-cell development and
survival. Variations in the gene encoding BAFF-R, TNFRSF13C, may affect
BAFF-R function and consequently the ability to generate an adequate
antibody response. One BAFF-R variation, rs77874543 leading to the
amino acid variation P21R and affecting BAFF binding, is quite common
in the general population (7.5% in Europeans [23]) and slightly more
frequent in individuals with CVID [11]. Oncemore, we did not find a dif-
ference between RRTI patients and controls in the presence of the
rs77874543 variation.
Our finding that MBL2 secretor genotypes were more often defi-
cient/low in controls than in patients is counterintuitive. It suggests a
protective effect of low MBL activity against RRTI, while airway infec-
tions are commonly linked to MBL deficiency [24,25]. In addition, nu-
merous studies have shown that MBL deficiency is associated with
increased severity and outcomeof bacterial infection in critically ill indi-
viduals. For instance, in patients with systemic inflammatory response
syndromeMBL insufficiency is associatedwith development of (severe)
sepsis and septic shock [26]. In patients with community acquired
pneumonia, MBL insufficiency is associated with sepsis severity and
mortality [25]. MBL deficiency alone does, however, not affect the inci-
dence of infectious diseases or mortality as concluded in a large cohort
study of adults (n = 9245) in Denmark [27]. Importantly, in that










Fig. 4. In many elderly individuals MBL activity does not correspond withMBL2 secretor
genotype. MBL activity was measured in serum of all individuals and MBL2 secretor
genotypes (high, intermediate, low and deficient) were determined by sequencing the
MBL2 gene. Red circles indicate RRTI patients, green triangles indicate controls. The
black horizontal line indicates the median. The grey pattern indicates the area where
samples are completely (0% activity) or partially (activity between 0 and 10%) deficient.
118 E. van de Vosse et al. / Clinical Immunology 180 (2017) 111–119genotypes. Our study shows that at least in elderly people (N45 years
old) MBL production and activity is declined and may no longer corre-
late with MBL2 secretor genotype.
This potential protective effect of lowMBL activity against RRTI obvi-
ously needs verification in a study involving large numbers of patients
and controls. However, it is illustrative that we not only found signifi-
cantly more controls than RRTI patients with low or deficientMBL2 se-
cretor genotypes, but also a somewhat higher percentage of controls
than patients with low or absent MBL functional activity. A relation be-
tween an intermediate versushigh (or low)MBL2 secretor genotype and
lifespan in an elderly population, not selected for any disease pheno-
type, has been reported previously [28]. The authors suggest that having
an intermediate haplotype is an evolutionary advantage. Indeed, the rel-
atively high frequency of deficient alleles in the general population sug-
gests that this must be the case [29]. Importantly, low MBL activity has
been associated with less severe malaria [30] and less frequent and less
severe leishmaniasis [31]. Beneficial effects of MBL deficiency may exist
for other diseases that have not been investigated thus far, where higher
MBL activity contributes to mortality, resulting in selection at an ad-
vanced age of individuals carrying null alleles.
Despite the above described difference inMBL functional activity be-
tween controls and patients, we found high percentages of functional
MBL deficiency in our study population as a whole, both in patients
(53%) and in controls (65%). These percentages were much higher
than expected based on the prevalence of functional MBL deficiency in
the general population (20–25% in all populations analyzed, [29]).
MBL2 secretor genotypes often did not match this MBL deficiency, nei-
ther in controls nor in patients, although we did find an overall correla-
tion betweenMBL2 secretor genotype andMBL activity. Altogether, our
findings suggest that in elderly people the activity of the MBL protein
becomes impaired. We excluded presence of an inhibitory serum factor
as an underlying mechanism, and will focus in future studies on other
options explaining this acquired MBL deficiency in the elderly popula-
tion at large.
This pilot study explores an underlying cause of disease in elderly
patients presenting with late-onset RRTI, which would disqualify this
possible sign of dysfunctioning immunity as a typical old age ailment.
Within the limits of the study we did not obtain clear evidence for an
immune defect discriminative for late-onset RRTI. It is of course possiblethat many of these patients have unknown combinations of polymor-
phisms in other genes involved, each leading to RRTI in a different way.
In summary, we found that elderly people in general are often MBL
deficient, a condition that is potentially acquired in older age, and that
many have lowvaccination responses to PPV-23which do not necessar-
ily culminate in clinically overt SPAD.
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